Urology Plenary Session News Today : Breaking News, Live Updates & Top Stories | Vimarsana

- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy -

San antonioUnited statesAmbaw belleteLaurence wattsGaryd steinbergMarkd tysonCretostimogene grenadenorepvecCalmette guerinDrug administrationGlobe newswire cg oncology incAmerican urological associationNon muscle invasive bladder cancerBacillus calmette guerinPractice changing clinical trialsUrology plenary sessionUrologic oncologist